Le Lézard
Classified in: Health, Business
Subjects: ERN, ACC

ZINZINO AB (PUBL): PRELIMINARY SALES REPORT NOVEMBER 2023


Zinzino group revenue increased with a total of 24 %, compared with the previous year.

GOTHENBURG, Sweden, Dec. 5, 2023 /PRNewswire/ -- The revenue in November for Zinzino's sales markets increased by 24 % and amounted to SEK 199.6 (161.2) million. Faun Pharma's external sales increased by 29 % and amounted to SEK 7.6 (5.9) million. Overall, the Group increased revenues by 24 % to SEK 207.2 (167.1) million compared with the previous year.

Accumulated revenue for January ? November 2023 increased by 22 % to SEK 1609.6 (1314.2) million.

Revenues were distributed as follows:

Regions,MSEK

23-Nov

22-Nov

Change

YTD 2023

YTD 2022

Change

The Nordics

29.3

28.4

3 %

274.9

292.3

-6 %

Central Europe

50.9

38.6

32 %

399.7

263,0

52 %

East Europe

49.8

46.1

8 %

362.3

314.2

15 %

South & West Europe

34.5

19.6

76 %

241,0

149.7

61 %

The Baltics

14.8

11.1

33 %

91.7

70.7

30 %

North America

12.6

8,0

58 %

97.5

71.6

36 %

Asia-Pacific

6.2

7.9

-22 %

45.8

71.7

-36 %

Africa

1.5

1.5

0 %

11.7

8.8

33 %

Zinzino

199.6

161.2

24 %

1524.6

1 242,0

23 %

Faun Pharma

7.6

5.9

29 %

85,0

72.2

18 %

Zinzino Group

207.2

167.1

24 %

1609.6

1314.2

22 %

Countries in regions:
-The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden
-Central Europe: Austria, Germany, Switzerland
-East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania
-South & West Europe: Cyprus, France, Greece, Italy, Luxembourg, Malta, Netherlands, Slovenia, Spain, United Kingdom, Belgium, Ireland, Turkey
-The Baltics: Estonia, Latvia, Lithuania
-North America: Canada, USA, Mexico
-Asia-Pacific: Australia, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand
-Africa: South Africa

For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com

Pictures for publication free of charge:
[email protected]

Certified Adviser:
Carnegie Investment Bank AB (publ)

The following files are available for download:

https://mb.cision.com/Public/10976/3887912/a6e5e88b819bbed1.pdf

2311 Pressrelease Salesreport EN

 


These press releases may also interest you

at 18:12
Functional Food Ingredients Market size is set to grow by USD 53.14 bn from 2024-2028, increased demand for functional food ingredients from probiotics segment to boost the market growth, Technavio
The global functional food ingredients market size is estimated to grow by USD 53.14 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 7.38% during the forecast period. ...

at 17:55
City of Hope Awarded $5.4 Million CIRM Grant to Create a Stem Cell Laboratory and Expand Access to State-of-the-Art Disease Models and Technology Among a Diverse Scientific Community
City of Hope®, one of the largest cancer research and treatment organizations in the United States, has been awarded $5.4 million from the California Institute for Regenerative Medicine (CIRM) to build and fund a stem cell research laboratory on its...

at 17:25
Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Talphera, Inc. , ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that the Board of Directors of Talphera has granted...

at 16:56
JDRF-Authored Paper Shows Pathway to Accelerate Disease-Modifying Therapies for People with Type 1 Diabetes
A paper published in the June edition of the Journal Diabetes demonstrates that C-peptide, a biomarker that indicates the production of insulin, is a validated surrogate endpoint, or predictor of clinical benefit, for clinical trials of...

at 16:28
Insmed Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 ARISE Study Of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with NTM Lung Disease Caused by MAC at American Thoracic Society 2024 International Conference Plenary Session
?Patients Treated with ARIKAYCE Plus Macrolide-Based Background Regimen Had Meaningfully Greater Improvements in Respiratory Symptoms vs. Macrolide-Based Background Regimen Alone, As Measured By the QOL-B Respiratory Domain Instrument? ?QOL-B...

at 16:20
TOP-RANKED HEALTHCARE CONSULTING FIRM EXPANDS ROSTER, DEEPENS LEADERSHIP
Jarrard Inc., a leading national healthcare strategic communications consultancy, has expanded by 10 percent, adding seven new professionals to address the increasing demand for its healthcare advisory services. The team now includes 81 full-time...

More news about Health...


News published on and distributed by: